Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034
Description
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034
The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the value likely to reach USD 52.03 billion by 2034.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis
The global Glucagon-Like Peptide-1 (GLP-1) agonists market is experiencing significant growth due to the increasing prevalence of type 2 diabetes and obesity. GLP-1 agonists are widely used for glycaemic control and weight management, offering advantages such as improved insulin secretion, delayed gastric emptying, and appetite suppression. These drugs have gained substantial market traction due to their superior efficacy compared to traditional diabetes treatments. The market is being driven by expanding therapeutic applications, technological advancements in drug delivery, and rising healthcare awareness.
Market Drivers
Rising Prevalence of Type 2 Diabetes and Obesity – Increasing sedentary lifestyles, poor dietary habits, and genetic predispositions have led to a global surge in type 2 diabetes and obesity, fuelling demand for GLP-1 agonists.
Favourable Clinical Outcomes – GLP-1 agonists demonstrate significant advantages over conventional treatments, including weight loss benefits, lower hypoglycaemia risks, and cardiovascular protection, increasing their adoption.
Advancements in Drug Formulations and Delivery Methods – Innovations such as once-weekly dosing, oral formulations, and combination therapies have enhanced patient compliance, boosting market growth.
Government and Private Healthcare Initiatives – Supportive policies, subsidies, and reimbursement programmes for diabetes and obesity management are accelerating market expansion, particularly in developed economies.
Market Challenges
High Cost of GLP-1 Agonists – Despite their effectiveness, the high cost of these drugs limits access, especially in low- and middle-income countries.
Adverse Side Effects – Common side effects such as nausea, vomiting, and gastrointestinal discomfort can lead to treatment discontinuation, affecting market penetration.
Regulatory and Reimbursement Barriers – Stringent approval processes and varying reimbursement policies across regions pose challenges for market growth.
Competition from Alternative Therapies – The availability of other diabetes and weight management treatments, including SGLT2 inhibitors and insulin therapies, creates competitive pressure.
Future Opportunities
Expansion of Indications Beyond Diabetes – Ongoing research into GLP-1 agonists for conditions such as cardiovascular diseases and neurodegenerative disorders could expand market potential.
Growth in Emerging Markets – Increasing healthcare infrastructure and rising awareness in Asia-Pacific and Latin America offer lucrative growth opportunities.
Development of Next-Generation Therapies – Innovations in dual and triple receptor agonists promise improved efficacy and broader therapeutic applications.
Strategic Collaborations and Biosimilar Development – Partnerships between pharmaceutical companies and the emergence of biosimilars could enhance affordability and market reach.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
The global GLP-1 agonists market is witnessing rapid expansion, driven by increasing diabetes prevalence and evolving treatment approaches. Key trends highlight advancements in drug formulations, rising adoption for weight management, and expanding therapeutic applications.
1. Shift Towards Once-Weekly and Oral Formulations
Pharmaceutical companies are focusing on developing extended-release formulations and oral GLP-1 agonists to improve patient compliance. Once-weekly injections and pill-based alternatives, such as semaglutide, are gaining traction, reducing the burden of frequent dosing.
2. Increasing Use for Obesity and Weight Management
GLP-1 agonists are now widely prescribed for obesity management beyond diabetes treatment. The growing recognition of their weight-loss benefits has led to regulatory approvals and increased adoption in non-diabetic populations seeking effective weight control solutions.
3. Cardiovascular and Metabolic Benefits Driving Adoption
Recent studies highlight the cardiovascular benefits of GLP-1 agonists, including reduced heart disease risks. These findings have led to broader clinical acceptance and integration into treatment guidelines for patients with metabolic disorders.
4. Expanding Applications Beyond Diabetes
Research is exploring the potential of GLP-1 agonists in treating conditions such as non-alcoholic fatty liver disease (NAFLD), neurodegenerative disorders, and polycystic ovary syndrome (PCOS). This diversification is expected to create new revenue streams for market players.
5. Increasing Investment in Biosimilars and Generics
As patents for leading GLP-1 agonists approach expiration, pharmaceutical companies are investing in biosimilar and generic alternatives to enhance affordability and market penetration, particularly in developing regions.
6. Strategic Partnerships and Mergers Accelerating Market Growth
Major pharmaceutical companies are engaging in collaborations and acquisitions to expand their GLP-1 product portfolios. Partnerships between biotech firms and established drug manufacturers are fostering innovation in drug development and delivery systems.
7. Digital Health Integration Enhancing Treatment Monitoring
The rise of digital health solutions, including smart insulin pens and AI-driven treatment monitoring, is improving adherence and treatment outcomes for GLP-1 agonist users, further driving market expansion.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation
Market Breakup by Drugs
Dulaglutide
Exenatide
Liraglutide
Tirzepatide
Lixisenatide
Semaglutide
The global GLP-1 agonists market is driven by key drugs such as dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. Among these, semaglutide dominates due to its efficacy in both type 2 diabetes and weight management. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is gaining traction for superior glycaemic control and weight loss. Dulaglutide and liraglutide maintain strong market presence due to their cardiovascular benefits. Continuous innovation in formulations, including extended-release injections and oral alternatives, is expected to drive market expansion, enhancing patient adherence and accessibility worldwide.
Market Breakup by Application
Type 2 Diabetes Mellitus
Obesity
GLP-1 agonists are primarily used for type 2 diabetes mellitus treatment, where they improve insulin secretion, reduce glucose levels, and lower cardiovascular risks. However, their increasing adoption for obesity management is transforming the market. Rising obesity rates and regulatory approvals for weight loss indications are accelerating growth. With growing awareness of metabolic health, GLP-1 agonists are expected to play a central role in obesity therapy, further expanding the market and creating new revenue streams for pharmaceutical companies.
Market Breakup by Route of Administration
Parenteral
Oral
Parenteral administration dominates the GLP-1 agonists market, with most drugs available as subcutaneous injections. Advances in once-weekly formulations have improved patient compliance, reducing injection frequency. However, the emergence of oral GLP-1 agonists, such as oral semaglutide, is revolutionising the market by offering a non-invasive alternative. The growing preference for oral drugs is expected to drive market growth, particularly in patients hesitant to use injectable therapies, expanding accessibility and adoption globally.
Market Breakup by End User
Hospitals
Specialty Clinics
Academic and Research Institutes
Others
Hospitals account for the largest market share due to the increasing prevalence of diabetes-related hospitalisations and access to advanced treatments. Specialty clinics are witnessing significant growth as personalised diabetes and obesity management become more prevalent. Academic and research institutes play a crucial role in clinical trials and drug development. The others segment, including homecare settings, is expanding due to rising adoption of GLP-1 agonists for self-administration, driven by patient convenience and telemedicine advancements.
Market Breakup by Distribution
Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hospital pharmacies lead the distribution
of GLP-1 agonists due to their strong integration with healthcare facilities and availability of prescription-based treatments. Retail pharmacies hold a substantial share, catering to outpatient prescriptions and chronic disease management. Online pharmacies are rapidly growing, driven by digital healthcare adoption, improved accessibility, and increasing patient preference for doorstep delivery, particularly in developed markets. The expansion of e-commerce in pharmaceuticals is expected to boost the online pharmacy segment significantly.
Market Breakup by Region
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
North America dominates the GLP-1 agonists market due to high diabetes prevalence, strong healthcare infrastructure, and early adoption of innovative therapies. Europe follows closely, benefiting from supportive government policies and rising obesity rates. Asia-Pacific is witnessing the fastest growth, driven by increasing healthcare investments, a growing diabetic population, and expanding pharmaceutical access. Latin America and the Middle East & Africa are emerging markets, with improving healthcare systems and rising awareness boosting GLP-1 agonist adoption. Expanding regulatory approvals and market penetration in developing regions will further fuel global market growth.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Competitive Landscape
The global GLP-1 agonists market is highly competitive, with major pharmaceutical companies focusing on innovation, strategic partnerships, and market expansion. Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca plc, Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc are the key players driving market growth. Companies are actively engaging in mergers and acquisitions to strengthen their product portfolios and global presence. Research initiatives focus on next-generation GLP-1 agonists and combination therapies. Product introductions include oral formulations and extended-release injections. Strategic partnerships with biotech firms and healthcare providers are accelerating innovation and accessibility.
Key Questions Answered
in the Report
· What factors are driving the growth of the global GLP-1 agonists market?
· How is the rising prevalence of diabetes and obesity influencing GLP-1 agonist adoption?
· What are the advantages of GLP-1 agonists over traditional diabetes treatments?
· How are oral GLP-1 agonists impacting the market compared to injectable formulations?
· What role do research initiatives and clinical trials play in advancing GLP-1 therapies?
· Which pharmaceutical companies are leading the global GLP-1 agonists market?
· How are mergers, acquisitions, and partnerships shaping competition in the GLP-1 market?
· What challenges does the GLP-1 agonists market face in terms of affordability and accessibility?
· How is digital health technology improving patient adherence to GLP-1 agonist treatments?
· What future opportunities exist for GLP-1 agonists beyond diabetes and obesity management?
Key Benefits for Stakeholders
· The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global glucagon-like peptide-1 (GLP-1) Agonists market from 2018-2034.
· The research report provides the latest information on the market drivers, challenges, and opportunities in the global glucagon-like peptide-1 (GLP-1) Agonists market.
· The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
· Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global glucagon-like peptide-1 (GLP-1) Agonists industry and its attractiveness.
· The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the value likely to reach USD 52.03 billion by 2034.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis
The global Glucagon-Like Peptide-1 (GLP-1) agonists market is experiencing significant growth due to the increasing prevalence of type 2 diabetes and obesity. GLP-1 agonists are widely used for glycaemic control and weight management, offering advantages such as improved insulin secretion, delayed gastric emptying, and appetite suppression. These drugs have gained substantial market traction due to their superior efficacy compared to traditional diabetes treatments. The market is being driven by expanding therapeutic applications, technological advancements in drug delivery, and rising healthcare awareness.
Market Drivers
Rising Prevalence of Type 2 Diabetes and Obesity – Increasing sedentary lifestyles, poor dietary habits, and genetic predispositions have led to a global surge in type 2 diabetes and obesity, fuelling demand for GLP-1 agonists.
Favourable Clinical Outcomes – GLP-1 agonists demonstrate significant advantages over conventional treatments, including weight loss benefits, lower hypoglycaemia risks, and cardiovascular protection, increasing their adoption.
Advancements in Drug Formulations and Delivery Methods – Innovations such as once-weekly dosing, oral formulations, and combination therapies have enhanced patient compliance, boosting market growth.
Government and Private Healthcare Initiatives – Supportive policies, subsidies, and reimbursement programmes for diabetes and obesity management are accelerating market expansion, particularly in developed economies.
Market Challenges
High Cost of GLP-1 Agonists – Despite their effectiveness, the high cost of these drugs limits access, especially in low- and middle-income countries.
Adverse Side Effects – Common side effects such as nausea, vomiting, and gastrointestinal discomfort can lead to treatment discontinuation, affecting market penetration.
Regulatory and Reimbursement Barriers – Stringent approval processes and varying reimbursement policies across regions pose challenges for market growth.
Competition from Alternative Therapies – The availability of other diabetes and weight management treatments, including SGLT2 inhibitors and insulin therapies, creates competitive pressure.
Future Opportunities
Expansion of Indications Beyond Diabetes – Ongoing research into GLP-1 agonists for conditions such as cardiovascular diseases and neurodegenerative disorders could expand market potential.
Growth in Emerging Markets – Increasing healthcare infrastructure and rising awareness in Asia-Pacific and Latin America offer lucrative growth opportunities.
Development of Next-Generation Therapies – Innovations in dual and triple receptor agonists promise improved efficacy and broader therapeutic applications.
Strategic Collaborations and Biosimilar Development – Partnerships between pharmaceutical companies and the emergence of biosimilars could enhance affordability and market reach.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
The global GLP-1 agonists market is witnessing rapid expansion, driven by increasing diabetes prevalence and evolving treatment approaches. Key trends highlight advancements in drug formulations, rising adoption for weight management, and expanding therapeutic applications.
1. Shift Towards Once-Weekly and Oral Formulations
Pharmaceutical companies are focusing on developing extended-release formulations and oral GLP-1 agonists to improve patient compliance. Once-weekly injections and pill-based alternatives, such as semaglutide, are gaining traction, reducing the burden of frequent dosing.
2. Increasing Use for Obesity and Weight Management
GLP-1 agonists are now widely prescribed for obesity management beyond diabetes treatment. The growing recognition of their weight-loss benefits has led to regulatory approvals and increased adoption in non-diabetic populations seeking effective weight control solutions.
3. Cardiovascular and Metabolic Benefits Driving Adoption
Recent studies highlight the cardiovascular benefits of GLP-1 agonists, including reduced heart disease risks. These findings have led to broader clinical acceptance and integration into treatment guidelines for patients with metabolic disorders.
4. Expanding Applications Beyond Diabetes
Research is exploring the potential of GLP-1 agonists in treating conditions such as non-alcoholic fatty liver disease (NAFLD), neurodegenerative disorders, and polycystic ovary syndrome (PCOS). This diversification is expected to create new revenue streams for market players.
5. Increasing Investment in Biosimilars and Generics
As patents for leading GLP-1 agonists approach expiration, pharmaceutical companies are investing in biosimilar and generic alternatives to enhance affordability and market penetration, particularly in developing regions.
6. Strategic Partnerships and Mergers Accelerating Market Growth
Major pharmaceutical companies are engaging in collaborations and acquisitions to expand their GLP-1 product portfolios. Partnerships between biotech firms and established drug manufacturers are fostering innovation in drug development and delivery systems.
7. Digital Health Integration Enhancing Treatment Monitoring
The rise of digital health solutions, including smart insulin pens and AI-driven treatment monitoring, is improving adherence and treatment outcomes for GLP-1 agonist users, further driving market expansion.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation
Market Breakup by Drugs
Dulaglutide
Exenatide
Liraglutide
Tirzepatide
Lixisenatide
Semaglutide
The global GLP-1 agonists market is driven by key drugs such as dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. Among these, semaglutide dominates due to its efficacy in both type 2 diabetes and weight management. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is gaining traction for superior glycaemic control and weight loss. Dulaglutide and liraglutide maintain strong market presence due to their cardiovascular benefits. Continuous innovation in formulations, including extended-release injections and oral alternatives, is expected to drive market expansion, enhancing patient adherence and accessibility worldwide.
Market Breakup by Application
Type 2 Diabetes Mellitus
Obesity
GLP-1 agonists are primarily used for type 2 diabetes mellitus treatment, where they improve insulin secretion, reduce glucose levels, and lower cardiovascular risks. However, their increasing adoption for obesity management is transforming the market. Rising obesity rates and regulatory approvals for weight loss indications are accelerating growth. With growing awareness of metabolic health, GLP-1 agonists are expected to play a central role in obesity therapy, further expanding the market and creating new revenue streams for pharmaceutical companies.
Market Breakup by Route of Administration
Parenteral
Oral
Parenteral administration dominates the GLP-1 agonists market, with most drugs available as subcutaneous injections. Advances in once-weekly formulations have improved patient compliance, reducing injection frequency. However, the emergence of oral GLP-1 agonists, such as oral semaglutide, is revolutionising the market by offering a non-invasive alternative. The growing preference for oral drugs is expected to drive market growth, particularly in patients hesitant to use injectable therapies, expanding accessibility and adoption globally.
Market Breakup by End User
Hospitals
Specialty Clinics
Academic and Research Institutes
Others
Hospitals account for the largest market share due to the increasing prevalence of diabetes-related hospitalisations and access to advanced treatments. Specialty clinics are witnessing significant growth as personalised diabetes and obesity management become more prevalent. Academic and research institutes play a crucial role in clinical trials and drug development. The others segment, including homecare settings, is expanding due to rising adoption of GLP-1 agonists for self-administration, driven by patient convenience and telemedicine advancements.
Market Breakup by Distribution
Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hospital pharmacies lead the distribution
of GLP-1 agonists due to their strong integration with healthcare facilities and availability of prescription-based treatments. Retail pharmacies hold a substantial share, catering to outpatient prescriptions and chronic disease management. Online pharmacies are rapidly growing, driven by digital healthcare adoption, improved accessibility, and increasing patient preference for doorstep delivery, particularly in developed markets. The expansion of e-commerce in pharmaceuticals is expected to boost the online pharmacy segment significantly.
Market Breakup by Region
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
North America dominates the GLP-1 agonists market due to high diabetes prevalence, strong healthcare infrastructure, and early adoption of innovative therapies. Europe follows closely, benefiting from supportive government policies and rising obesity rates. Asia-Pacific is witnessing the fastest growth, driven by increasing healthcare investments, a growing diabetic population, and expanding pharmaceutical access. Latin America and the Middle East & Africa are emerging markets, with improving healthcare systems and rising awareness boosting GLP-1 agonist adoption. Expanding regulatory approvals and market penetration in developing regions will further fuel global market growth.
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Competitive Landscape
The global GLP-1 agonists market is highly competitive, with major pharmaceutical companies focusing on innovation, strategic partnerships, and market expansion. Eli Lilly and Company, Sanofi, Novo Nordisk A/S, AstraZeneca plc, Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc are the key players driving market growth. Companies are actively engaging in mergers and acquisitions to strengthen their product portfolios and global presence. Research initiatives focus on next-generation GLP-1 agonists and combination therapies. Product introductions include oral formulations and extended-release injections. Strategic partnerships with biotech firms and healthcare providers are accelerating innovation and accessibility.
Key Questions Answered
in the Report
· What factors are driving the growth of the global GLP-1 agonists market?
· How is the rising prevalence of diabetes and obesity influencing GLP-1 agonist adoption?
· What are the advantages of GLP-1 agonists over traditional diabetes treatments?
· How are oral GLP-1 agonists impacting the market compared to injectable formulations?
· What role do research initiatives and clinical trials play in advancing GLP-1 therapies?
· Which pharmaceutical companies are leading the global GLP-1 agonists market?
· How are mergers, acquisitions, and partnerships shaping competition in the GLP-1 market?
· What challenges does the GLP-1 agonists market face in terms of affordability and accessibility?
· How is digital health technology improving patient adherence to GLP-1 agonist treatments?
· What future opportunities exist for GLP-1 agonists beyond diabetes and obesity management?
Key Benefits for Stakeholders
· The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global glucagon-like peptide-1 (GLP-1) Agonists market from 2018-2034.
· The research report provides the latest information on the market drivers, challenges, and opportunities in the global glucagon-like peptide-1 (GLP-1) Agonists market.
· The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
· Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global glucagon-like peptide-1 (GLP-1) Agonists industry and its attractiveness.
· The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
300 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Overview
- 3.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Historical Value (2018-2024)
- 3.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Landscape*
- 5.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market: Product Landscape
- 5.2.1 Analysis By Drugs
- 5.2.2 Analysis By Application
- 5.2.3 Analysis By Route of Administration
- 6 Clinical Trials and Pipeline Analysis
- 6.1 Analysis by Trial Registration Year
- 6.2 Analysis by Trial Status
- 6.3 Analysis by Trial Phase
- 6.4 Analysis by Therapeutic Area
- 6.5 Analysis by Geography
- 6.6 Drug Pipeline Assessment
- 7 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Dynamics
- 7.1 Market Drivers and Constraints
- 7.2 SWOT Analysis
- 7.2.1 Strengths
- 7.2.2 Weaknesses
- 7.2.3 Opportunities
- 7.2.4 Threats
- 7.3 PESTEL Analysis
- 7.3.1 Political
- 7.3.2 Economic
- 7.3.3 Social
- 7.3.4 Technological
- 7.3.5 Legal
- 7.3.6 Environment
- 7.4 Porter’s Five Forces Model
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of New Entrants
- 7.4.4 Threat of Substitutes
- 7.4.5 Degree of Rivalry
- 7.5 Key Demand Indicators
- 7.6 Key Price Indicators
- 7.7 Industry Events, Initiatives, and Trends
- 7.8 Value Chain Analysis
- 8 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Segmentation (218-2034)
- 8.1 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 8.1.1 Market Overview
- 8.1.2 Dulaglutide
- 8.1.3 Exenatide
- 8.1.4 Liraglutide
- 8.1.5 Tirzepatide
- 8.1.6 Lixisenatide
- 8.1.7 Semaglutide
- 8.2 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 8.2.1 Market Overview
- 8.2.2 Type 2 Diabetes Mellitus
- 8.2.3 Obesity
- 8.3 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 8.3.1 Market Overview
- 8.3.2 Parenteral
- 8.3.3 Oral
- 8.4 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Specialty Clinics
- 8.4.4 Academic and Research Institutes
- 8.4.5 Others
- 8.5 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 8.5.1 Market Overview
- 8.5.2 Hospital Pharmacies
- 8.5.3 Retail Pharmacies
- 8.5.4 Online Pharmacies
- 8.6 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Region
- 8.6.1 Market Overview
- 8.6.2 North America
- 8.6.3 Europe
- 8.6.4 Asia Pacific
- 8.6.5 Latin America
- 8.6.6 Middle East and Africa
- 9 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 9.1 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 9.1.1 Market Overview
- 9.1.2 Dulaglutide
- 9.1.3 Exenatide
- 9.1.4 Liraglutide
- 9.1.5 Tirzepatide
- 9.1.6 Lixisenatide
- 9.1.7 Semaglutide
- 9.2 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 9.2.1 Market Overview
- 9.2.2 Type 2 Diabetes Mellitus
- 9.2.3 Obesity
- 9.3 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 9.3.1 Market Overview
- 9.3.2 Parenteral
- 9.3.3 Oral
- 9.4 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Specialty Clinics
- 9.4.4 Academic and Research Institutes
- 9.4.5 Others
- 9.5 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 9.5.1 Market Overview
- 9.5.2 Hospital Pharmacies
- 9.5.3 Retail Pharmacies
- 9.5.4 Online Pharmacies
- 9.6 North America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 9.6.1 United States of America
- 9.6.1.1 United States of America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 9.6.2 Canada
- 9.6.2.1 Canada Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 10.1 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10.1.1 Market Overview
- 10.1.2 Dulaglutide
- 10.1.3 Exenatide
- 10.1.4 Liraglutide
- 10.1.5 Tirzepatide
- 10.1.6 Lixisenatide
- 10.1.7 Semaglutide
- 10.2 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 10.2.1 Market Overview
- 10.2.2 Type 2 Diabetes Mellitus
- 10.2.3 Obesity
- 10.3 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 10.3.1 Market Overview
- 10.3.2 Parenteral
- 10.3.3 Oral
- 10.4 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospitals
- 10.4.3 Specialty Clinics
- 10.4.4 Academic and Research Institutes
- 10.4.5 Others
- 10.5 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 10.5.1 Market Overview
- 10.5.2 Hospital Pharmacies
- 10.5.3 Retail Pharmacies
- 10.5.4 Online Pharmacies
- 10.6 Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 10.6.1 United Kingdom
- 10.6.1.1 United Kingdom Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10.6.2 Germany
- 10.6.2.1 Germany Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10.6.3 France
- 10.6.3.1 France Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10.6.4 Italy
- 10.6.4.1 Italy Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 10.6.5 Others
- 11 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 11.1 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.1.1 Market Overview
- 11.1.2 Dulaglutide
- 11.1.3 Exenatide
- 11.1.4 Liraglutide
- 11.1.5 Tirzepatide
- 11.1.6 Lixisenatide
- 11.1.7 Semaglutide
- 11.2 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 11.2.1 Market Overview
- 11.2.2 Type 2 Diabetes Mellitus
- 11.2.3 Obesity
- 11.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Parenteral
- 11.3.3 Oral
- 11.4 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Specialty Clinics
- 11.4.4 Academic and Research Institutes
- 11.4.5 Others
- 11.5 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 11.5.1 Market Overview
- 11.5.2 Hospital Pharmacies
- 11.5.3 Retail Pharmacies
- 11.5.4 Online Pharmacies
- 11.6 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 11.6.1 China
- 11.6.1.1 China Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.6.2 Japan
- 11.6.2.1 Japan Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.6.3 India
- 11.6.3.1 India Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.6.4 ASEAN
- 11.6.4.1 ASEAN Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.6.5 Australia
- 11.6.5.1 Australia Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 11.6.6 Others
- 12 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 12.1 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 12.1.1 Market Overview
- 12.1.2 Dulaglutide
- 12.1.3 Exenatide
- 12.1.4 Liraglutide
- 12.1.5 Tirzepatide
- 12.1.6 Lixisenatide
- 12.1.7 Semaglutide
- 12.2 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 12.2.1 Market Overview
- 12.2.2 Type 2 Diabetes Mellitus
- 12.2.3 Obesity
- 12.3 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Parenteral
- 12.3.3 Oral
- 12.4 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Specialty Clinics
- 12.4.4 Academic and Research Institutes
- 12.4.5 Others
- 12.5 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 12.5.1 Market Overview
- 12.5.2 Hospital Pharmacies
- 12.5.3 Retail Pharmacies
- 12.5.4 Online Pharmacies
- 12.6 Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 12.6.1 Brazil
- 12.6.1.1 Brazil Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 12.6.2 Argentina
- 12.6.2.1 Argentina Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 12.6.3 Mexico
- 12.6.3.1 Mexico Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 12.6.4 Others
- 13 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (218-2034)
- 13.1 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 13.1.1 Market Overview
- 13.1.2 Dulaglutide
- 13.1.3 Exenatide
- 13.1.4 Liraglutide
- 13.1.5 Tirzepatide
- 13.1.6 Lixisenatide
- 13.1.7 Semaglutide
- 13.2 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Application
- 13.2.1 Market Overview
- 13.2.2 Type 2 Diabetes Mellitus
- 13.2.3 Obesity
- 13.3 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Parenteral
- 13.3.3 Oral
- 13.4 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by End User
- 13.4.1 Market Overview
- 13.4.2 Hospitals
- 13.4.3 Specialty Clinics
- 13.4.4 Academic and Research Institutes
- 13.4.5 Others
- 13.5 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Retail Pharmacies
- 13.5.4 Online Pharmacies
- 13.6 Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Country
- 13.6.1 Saudi Arabia
- 13.6.1.1 Saudi Arabia Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 13.6.2 United Arab Emirates
- 13.6.2.1 United Arab Emirates Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 13.6.3 Nigeria
- 13.6.3.1 Nigeria Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 13.6.4 South Africa
- 13.6.4.1 South Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market (2018-2034) by Drugs
- 13.6.5 Others
- 14 Regulatory Framework
- 14.1 Regulatory Overview
- 14.2 US FDA
- 14.3 EU EMA
- 14.4 INDIA CDSCO
- 14.5 JAPAN PMDA
- 14.6 Others
- 15 Patent Analysis
- 15.1 Analysis By Drug Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Drug Class of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Initiatives
- 18.3 Analysis by Joint Ventures
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.1.1 Market Share Analysis: Global
- 19.1.2 Market Share Analysis: North America
- 19.1.3 Market Share Analysis: Europe
- 19.1.4 Market Share Analysis: Asia Pacific
- 19.1.5 Market Share Analysis: Others
- 19.2 Eli Lilly and Company
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Development
- 19.2.5 Certifications
- 19.3 Sanofi
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Development
- 19.3.5 Certifications
- 19.4 Novo Nordisk A/S
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Development
- 19.4.5 Certifications
- 19.5 AstraZeneca plc
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Development
- 19.5.5 Certifications
- 19.6 Pfizer Inc.
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Development
- 19.6.5 Certifications
- 19.7 Boehringer Ingelheim
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Development
- 19.7.5 Certifications
- 19.8 F. Hoffmann-La Roche
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Development
- 19.8.5 Certifications
- 19.9 Amgen Inc.
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Development
- 19.9.5 Certifications
- 19.10 GlaxoSmithKline plc
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Development
- 19.10.5 Certifications
- 20 Global Glucagon-like Peptide-1 (GLP-1) Agonists Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
